Cost-Effectiveness Of Exenatide Versus Insulin Glargine And Versus Biphasic Insulin Aspart For The Treatment Of Type 2 Diabetes In Portugal: A Long-Term Health Economic Analysis
AuthID
P-003-1S9
P-003-1S9